-
Generic Ibrutinib Tablet Given Tentative FDA Approval in CLL/SLL, WM
25 Jul 2025 19:04 GMT
… 5 randomized, controlled trials, including the RESTONATE trial (NCT01578707).3 RESONATE … investigators randomized patients to treatment with ibrutinib or ofatumumab (Kesimpta), including … 47;/www.accessdata.fda.gov/drugsatfda_docs/appletter…
-
Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers
24 Jul 2025 19:18 GMT
… of 484 abbreviated new drug applications since the beginning … of treatment were eligible for enrollment on the trial.3 … a phase 2 trial (NCT02604511) from Dana-Farber Cancer Institute, in … ibrutinib (PCI-32765) versus ofatumumab in patients with relapsed or …
-
Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Analysis 2025 – Long-Term Investment & Planning Insights
24 Jul 2025 11:55 GMT
… Phase III clinical trials reached 33 … Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB … multiple sclerosis treatment. These drugs target specific … Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab
2 Immunosuppressants: …
-
Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial
11 Jul 2025 13:29 GMT
… ofatumumab.8–10 Notably, recent randomized controlled trials … of Inner Mongolia Medical University (Hohhot) … receipt of the treatment drug. This retrospective … treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial …
-
Global Multiple Sclerosis Treatment Market To Reach $31.55 Billion By 2029 With A Growth Rate Of 4.8%.
01 Jul 2025 10:56 GMT
… Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd …
3 By Symptomatic Treatments: Muscle Relaxants, Antidepressants, Anticonvulsants, Bladder Dysfunction Drugs
4 By …
-
Wearing Off Rates Higher in Ocrelizumab Than Ofatumumab, Study Suggests
02 Jun 2025 13:52 GMT
… symptom worsening while on medication than those prescribed ofatumumab (Kesimpta; Novartis). … medications to manage MS symptoms (68% vs 83%).
In the trial … with ocrelizumab, regardless of treatment duration. For ofatumumab, occurrence decreased with longer …
-
Pregnancy Outcomes in Ofatumumab-Treated Women Appear Consistent With General Population Rates
30 May 2025 20:15 GMT
… were treated with ofatumumab (Kesimpta; Novartis), an FDA-approved disease-modifying therapy … , drawing on cases from clinical trials and post marketing surveillance via … . ABSTRACT LBA14.
2. FDA approves Novartis Kesimpta® (ofatumumab), the first and only …
-
FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
19 Feb 2025 23:30 GMT
… information was limited, and FDA required the drug manufacturer, Secura Bio, to … , Grade ≥3 adverse events, and treatment modifications due to adverse events … in the DUO Trial, ITT population
Copiktra (N=160)
Ofatumumab (N=159 …
-
Statin use has ‘strong link’ to survival benefits for patients with certain blood cancers
12 May 2025 12:03 GMT
… addition of statin medications to contemporary therapies … recommend statins for cancer prevention or treatment based … trials — RESONATE, RESONATE-2, iLLUMINATE and HELIOS — in their study.
Each trial … drugs as monotherapy or in combination, including ofatumumab …
-
Statins May Improve Survival in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib
06 May 2025 20:00 GMT
… ibrutinib (Imbruvica; Janssen Biotech, AbbVie). The study findings … treatment. Statins have been shown to reduce mortality across cancer … data from 4 randomized trials: RESONATE (NCT01578707), RESONATE2 … (PCI-32765) versus ofatumumab in patients with relapsed …